Brazil

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

TLR9 Inhibitor for Cerebral Malaria

Eisai Co., Ltd.'s ER-820446 is a selective inhibitor of Toll Like Receptor 9 (TLR9) signaling. TLRs are mediators of innate immunity. In vitro, ER-820446 inhibits CpG oligonucleotide (TLR9 agonist)-mediated induction of transcription factors in TLR9 transfected cells and the production of proinflammatory cytokines in dendritic cells. In a short term in vivo model in mice, administration of ER-820446 prevented a systemic cytokine response to a s.c. challenge with CpG oligonucleotide.

Sanofi-aventis 'Most Neglected Diseases' Program

As part of its 5-year agreement with the World Health Organization (WHO) in 2006 to extend its partnership in sleeping sickness (see separate entry), sanofi-aventis also undertook to support a collaborative program with WHO to improve treatment for some 'most neglected diseases', namely leishmaniasis, Chagas disease and Buruli ulcer. Sanofi-aventis is providing USD 6.4 million to WHO over 5 years for development of training, diagnostics and optimization of treatment for leishmaniasis.

Saber para Reagir

According to a survey of 600 adolescents from the impoverished Sao Jorge community in the Brazilian city of Londrina, 60% do not use contraceptives and 30 percent have used illegal drugs. To protect these vulnerable teens from infectious diseases, ALIA began the Saber para Reagir (To Know Is to React) program. The program's workshops educate 80 participants at a time about sexually transmitted diseases (including HIV/AIDS), early pregnancy, correct use of male and female contraceptives, and citizen rights.

Rotavirus Vaccine Program

The Rotavirus Vaccine Program works to accelerate the introduction of new vaccines to treat rotavirus.

Renascer: Helping Poor Mothers in Brazil

Renascer provides medical and educational aid to mothers with chronically ill children living below the poverty line. 

Pneumococcal Conjugate Vaccine Programs

Pneumococcal disease takes the lives of 1.6 million people each year, including approximately 800,000 children before their fifth birthday. More than 90% of these deaths occur in developing countries. Its most common serious form, pneumonia, accounts for one in every four child deaths. GlaxoSmithKline and Pfizer have developed pneumococcal conjugate vaccines which protect against this major health threat.

Pfizer Global Health Partnerships

Pfizer has a responsibility to direct its resources and expertise to address the world's most enduring health challenges. Cancer is one of these challenges and Pfizer recognizes that only by working together with those who share a vision of a healthier world can we make a significant impact toward eradicating this disease that has outlived too many generations. Pfizer's Global Health Partnerships (GHP) Program is one approach it is taking to tackle the global cancer epidemic.

Pankararu Health & Culture Project

Pfizer and Associacio Sao de Sem Limites (Unlimited Health Association) have been working together on The Pankararu Health and Culture Project since 2005. The project provides 5,000 Pankararu Indians in townships located in the Borborema Mountain Range, in the arid interior of Pernambuco State, with basic health care information. Pfizer provides both financial and technical support to the program. The Pankararu population also suffers from long droughts, intense social discrimination, clan conflicts and territorial disputes.

Novo Nordisk: Haemophilia Foundation

The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005 to address the significant need to improve haemophilia treatment in developing countries, where it is not a healthcare priority and many patients go undiagnosed or are inadequately treated. Consequently, life expectancy for people with haemophilia is low and treatment with clotting factors is suboptimal. NNHF is an independent trust, located in Zurich, Switzerland, and funds programs to improve hemophilia care, treatment and awareness in the developing world.

Pages